Initiating Empagliflozin and Sacubitril/Valsartan Early After Acute Myocardial Infarction: Mechanistic Study
In this pig model of nonreperfused MI treated with beta-blocker, early initiation of empagliflozin reduced inflammation, improved nitric oxide bioavailability, increased protective liver lipids, and modified scar composition without affecting cardiac function or VT risk. With empagliflozin+sacubitril/valsartan treatment, scar collagen I and VT inducibility declined and left ventricular remodeling was enhanced.
Authors
- Núria Amigó (ORCID: https://orcid.org/0000-0002-0116-9145)
- Marta Tortajada (ORCID: https://orcid.org/0000-0003-2125-0810)
- Oriol Rodríguez‐Leor (ORCID: https://orcid.org/0000-0003-2657-5657)
- Albert Teis
- Elena Revuelta‐López (ORCID: https://orcid.org/0000-0001-8962-5936)
- Antoni Bayes-genis A (ORCID: https://orcid.org/0000-0002-3044-197X)
- Victoria Delgado (ORCID: https://orcid.org/0000-0002-9841-2737)
- Roger Villuendas (ORCID: https://orcid.org/0000-0001-9110-905X)
- Santiago Roura (ORCID: https://orcid.org/0000-0003-4063-9661)
- Esther Jorge (ORCID: https://orcid.org/0000-0002-2777-0000)
- Neus Martínez-Micaelo (ORCID: https://orcid.org/0000-0001-6101-2847)
- Francesc Poblador (ORCID: https://orcid.org/0009-0000-0526-0774)
- Felipe Bisbal (ORCID: https://orcid.org/0000-0002-4843-7063)
- Axel Sarrias (ORCID: https://orcid.org/0000-0001-6712-3097)
- Francisco Rafael Jimenez‐Trinidad (ORCID: https://orcid.org/0000-0002-5139-9774)
- Daina Martínez‐Falguera (ORCID: https://orcid.org/0000-0002-9439-0542)
- Edgar Fadeuilhe (ORCID: https://orcid.org/0000-0003-0079-224X)
- Víctor Bazán (ORCID: https://orcid.org/0000-0001-8072-7434)
- Júlia Aranyó
- Gemma Ferrer‐Curriu (ORCID: https://orcid.org/0000-0002-2651-649X)
- Carolina Gálvez‐Montón (ORCID: https://orcid.org/0000-0003-2254-9371)
- Idoia Dı́az-Güemes (ORCID: https://orcid.org/0000-0001-6047-2489)
- Montserrat Rigol (ORCID: https://orcid.org/0000-0002-3763-1282)
- Borja Montejo
Institutions
- Universitat de Vic - Universitat Central de Catalunya (ES)
- Universitat Autònoma de Barcelona (ES)
- Instituto de Salud Carlos III (ES)
- Hospital Clínic de Barcelona (ES)
- Hospital Sant Pau i Santa Tecla (ES)
- Badalona Serveis Assistencials (ES)
- Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (ES)
- Hospital Universitari Germans Trias i Pujol (ES)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Universitat de Barcelona (ES)
- University of Lausanne (CH)
Publication Details
- Journal
- Journal of the American Heart Association
- Published
- 2025-05-26
- DOI
- https://doi.org/10.1161/jaha.124.040214
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Edwards Lifesciences
- Ministerio de Ciencia, Innovación y Universidades
- Boehringer Ingelheim España
- JenaValve
- Generalitat de Catalunya
- Novo Nordisk
- Abbott Vascular
- Agència de Gestió d'Ajuts Universitaris i de Recerca
- Instituto de Salud Carlos III
- European Regional Development Fund
- Biosense Webster